Immunother Limited Company scientists have successfully combined multiple immune systems, to form an extremely strong immune system. The resultant immuno-therapeutic product (StignumX™) has been validated in mouse studies at our laboratory at the University of Toronto, to prevent both breast cancer and inflammatory bowel disease. We are confident that StignumX™ will also be effective for the prevention of other cancers and other inflammatory/autoimmune diseases.
Immunother Limited Company is a privately held biotech company that develops patented immuno-therapeutics based on immune network theory.